Chemical denaturation is becoming increasingly popular in the drug development process. On one hand, it allows for determining the free enthalpy (ΔG) of unfolding of monoclonal antibodies (mAbs), which directly correlates with the fraction of unfolded protein in solution and provides thermodynamic insight into mAb stability. On the other hand, it is a tool to predict the aggregation propensity and aggregation mechanism of mAbs. Chemical denaturation experiments are performed by measuring the fraction of unfolded protein (e.g. by measuring the F350/F330 ratio) in a gradient of denaturant concentrations. Common denaturants are 0-8 M GuaHCl, 0-10 M Urea. In order to record a sufficient number of data points for fitting, at least 24 different denaturant concentrations should be measured. In order to derive correct ΔG values from chemical denaturation experiments, it is of major importance to use fully equilibrated samples. The time required for full equilibration is however often unknown, and some of the current commercial instrument solutions to detect chemical unfolding combine sample preparation and detection, which might lead to unsufficient incubation times.
Looking for the optimal formulation for your biologics candidates?
NanoTemper tools can help
See more related content
Choosing the right stability characterization tool for your biologics research is a big commitment. You’re going to be screening and optimizing lots of candidates, and you’ll need data on thermal stab
How to measure stability, why it's important, and where it belongs in the workflow
Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.
Any researcher looking to better understand their protein’s behavior can benefit from the information provided by Dynamic Light Scattering (DLS). Here’s an overview of DLS and how it’s useful for...
Dynamic Light Scattering (DLS) is a technique that allows researchers to accurately size their biologic molecules and determine the distribution of particle sizes in a solution. In order to turn scatt
Join Thomas Schubert, CEO of 2bind, as he walks through experiments done on the Prometheus Panta to determine the optimal buffer for a vaccine candidate.
Development of therapeutic antibodies is a long and costly process. One key indicator of whether biologic candidates will be successful is stability. Prometheus enables rapid and precise characterizat
AbbVie preformulation is an early discovery biologics group working to optimise antibodies prior to downstream assays and clinical delivery. Join Brittney Mills, PhD, as she explains how AbbVie uses